R W Buckheit

Summary

Affiliation: Southern Research Institute
Country: USA

Publications

  1. ncbi request reprint Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection
    R W Buckheit
    Infectious Disease Research Department, Southern Research Institute, 431 Aviation Way, Frederick, MD 21701, USA
    Expert Opin Investig Drugs 10:1423-42. 2001
  2. pmc SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2
    R W Buckheit
    Infectious Disease Research Department, Southern Research Institute, Frederick, Maryland 21701, USA
    Antimicrob Agents Chemother 45:393-400. 2001
  3. ncbi request reprint Anti-HIV-1 activity of calanolides used in combination with other mechanistically diverse inhibitors of HIV-1 replication
    R W Buckheit
    Infectious Disease Research Department, Southern Research Institute, Frederick, MD, USA
    Antivir Chem Chemother 11:321-7. 2000
  4. ncbi request reprint Anti-human immunodeficiency virus type 1 (HIV-1) activity of 2'-fluoro-2',3'-dideoxyarabinosyladenine (F-ddA) used in combination with other mechanistically diverse inhibitors of HIV-1 replication
    R W Buckheit
    Microbiology Research Department, Southern Research Institute, Frederick, MD 21701, USA
    Antivir Chem Chemother 10:115-9. 1999
  5. pmc Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates
    R W Buckheit
    Virology Research Group, Southern Research Institute Frederick Research Center, Maryland 21701, USA
    Antimicrob Agents Chemother 41:831-7. 1997
  6. pmc Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide
    R W Buckheit
    Infectious Disease Research Department, Serquest Southern Research Institute, Frederick, Maryland 21701, USA
    Antimicrob Agents Chemother 43:1827-34. 1999
  7. ncbi request reprint PMTI, a broadly active unusual single-stranded polyribonucleotide, inhibits human immunodeficiency virus replication by multiple mechanisms
    R W Buckheit
    Microbiology Research Department, Southern Research Institute, Frederick, MD 21701, USA
    Antivir Chem Chemother 10:23-32. 1999
  8. pmc Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide
    R W Buckheit
    Virology Research Group, Southern Research Institute Frederick Research Center, Maryland 21701, USA
    Antimicrob Agents Chemother 39:2718-27. 1995
  9. ncbi request reprint Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor
    J B McMahon
    Laboratory of Drug Discovery Research and Development, National Cancer Institute, Frederick, Maryland, USA
    J Pharmacol Exp Ther 276:298-305. 1996
  10. ncbi request reprint Differential antiviral activity of two TIBO derivatives against the human immunodeficiency and murine leukemia viruses alone and in combination with other anti-HIV agents
    R W Buckheit
    Virology Research Division, Southern Research Institute Frederick Research Center, Maryland 21701
    AIDS Res Hum Retroviruses 9:1097-106. 1993

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection
    R W Buckheit
    Infectious Disease Research Department, Southern Research Institute, 431 Aviation Way, Frederick, MD 21701, USA
    Expert Opin Investig Drugs 10:1423-42. 2001
    ..This ongoing research and development should also consider the challenges of defining more effective use of existing therapeutic agents, including the non-nucleoside reverse transcriptase inhibitors (NNRTIs)...
  2. pmc SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2
    R W Buckheit
    Infectious Disease Research Department, Southern Research Institute, Frederick, Maryland 21701, USA
    Antimicrob Agents Chemother 45:393-400. 2001
    ..On the basis of its therapeutic index and multiple mechanisms of anti-HIV action, SJ-3366 represents an exciting new compound for use in HIV-infected individuals...
  3. ncbi request reprint Anti-HIV-1 activity of calanolides used in combination with other mechanistically diverse inhibitors of HIV-1 replication
    R W Buckheit
    Infectious Disease Research Department, Southern Research Institute, Frederick, MD, USA
    Antivir Chem Chemother 11:321-7. 2000
    ..Combination assays with the (+)-calanolide A-resistant strain yielded identical results as seen with the wild-type virus, although the concentration of the calanolides had to be increased...
  4. ncbi request reprint Anti-human immunodeficiency virus type 1 (HIV-1) activity of 2'-fluoro-2',3'-dideoxyarabinosyladenine (F-ddA) used in combination with other mechanistically diverse inhibitors of HIV-1 replication
    R W Buckheit
    Microbiology Research Department, Southern Research Institute, Frederick, MD 21701, USA
    Antivir Chem Chemother 10:115-9. 1999
    ..No evidence of either combination toxicity or antagonistic antiviral activity was detected with any of the tested compounds...
  5. pmc Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates
    R W Buckheit
    Virology Research Group, Southern Research Institute Frederick Research Center, Maryland 21701, USA
    Antimicrob Agents Chemother 41:831-7. 1997
    ..The favorable anti-HIV properties of the UC compounds suggest they should be considered for further clinical development...
  6. pmc Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide
    R W Buckheit
    Infectious Disease Research Department, Serquest Southern Research Institute, Frederick, Maryland 21701, USA
    Antimicrob Agents Chemother 43:1827-34. 1999
    ....
  7. ncbi request reprint PMTI, a broadly active unusual single-stranded polyribonucleotide, inhibits human immunodeficiency virus replication by multiple mechanisms
    R W Buckheit
    Microbiology Research Department, Southern Research Institute, Frederick, MD 21701, USA
    Antivir Chem Chemother 10:23-32. 1999
    ..These results suggest that the homopolyribonucleotide PMTI blocks HIV replication in human cells at its earliest stages by multiple mechanisms, inhibition of virus entry and inhibition of RT...
  8. pmc Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide
    R W Buckheit
    Virology Research Group, Southern Research Institute Frederick Research Center, Maryland 21701, USA
    Antimicrob Agents Chemother 39:2718-27. 1995
    ..The merits of selecting potential candidate anti-HIV agents to be used in rational combination drugs design as part of an armamentarium of highly active anti-HIV compounds are discussed...
  9. ncbi request reprint Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor
    J B McMahon
    Laboratory of Drug Discovery Research and Development, National Cancer Institute, Frederick, Maryland, USA
    J Pharmacol Exp Ther 276:298-305. 1996
    ..The favorable physical characteristics, lack of toxicity, potency and bioavailability of UC 38 may make it a candidate for combination chemotherapy of acquired immune deficiency syndrome...
  10. ncbi request reprint Differential antiviral activity of two TIBO derivatives against the human immunodeficiency and murine leukemia viruses alone and in combination with other anti-HIV agents
    R W Buckheit
    Virology Research Division, Southern Research Institute Frederick Research Center, Maryland 21701
    AIDS Res Hum Retroviruses 9:1097-106. 1993
    ..Additive to slightly synergistic results were obtained in combinations with ddI and phosphonoformic acid whereas additive to antagonistic activity was detected in combination with dextran sulfate...
  11. ncbi request reprint The role of genotypic heterogeneity in wild type virus populations on the selection of nonnucleoside reverse transcriptase inhibitor-resistant viruses
    T L Kinjerski
    Virology Research Group, Southern Research Institute, Frederick Research Center, Maryland 21701, USA
    Antiviral Res 33:109-15. 1997
    ....
  12. pmc Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins
    W G Rice
    Laboratory of Antiviral Drug Mechanisms, National Cancer Institute Frederick Cancer Research and Development Center, Frederick, Maryland 21702 1201, USA
    Antimicrob Agents Chemother 41:419-26. 1997
    ..NSC 624151 provides a scaffold from which medicinal chemists can develop novel compounds for the therapeutic treatment of HIV infection...
  13. ncbi request reprint Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1
    M J Currens
    Laboratory of Drug Discovery Research and Development, National Cancer Institute, Frederick, Cancer Research and Development Center, Maryland 21702 1201, USA
    J Pharmacol Exp Ther 279:645-51. 1996
    ..The study substantially supports the conclusion that calanolide A represents a novel subclass of nonnucleoside RT inhibitor which merits consideration for anti-HIV drug development...
  14. ncbi request reprint Polyamine pools in HIV-infected cells
    E L White
    Southern Research Institute, Birmingham, Alabama 35205, USA
    J Acquir Immune Defic Syndr Hum Retrovirol 17:101-3. 1998
    ..Our results indicate that inhibitors of this pathway will not be therapeutically useful in the treatment of AIDS...